https://www.openbell.ai/ 2026-10-16T13:44:18.026Z hourly 1.0 https://www.openbell.ai/support 2026-10-16T13:44:18.026Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-16T13:44:18.026Z monthly 0.5 https://www.openbell.ai/terms 2026-10-16T13:44:18.026Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-16T13:44:18.026Z hourly 0.8 https://www.openbell.ai/news/ASTS:1792158170112 2026-10-16T13:42:50.112Z daily 0.9 https://cdn.brandfetch.io/ASTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is AST SpaceMobile Stock Falling Friday? AST SpaceMobile Inc. (NASDAQ: ASTS) experienced a decline in stock price as investors took profits after a previous 5.51% rebound. The drop followed a downgrade by Piper Sandler analyst Alexander Potter, who reduced his rating from Overweight to Neutral and cut the price forecast from $98 to $54. Concerns were raised regarding delays in satellite deployments and increased competition from SpaceX, which is expanding its market presence. The stock was trading at $43.68, close to its 52-week low of $42.00. https://www.openbell.ai/news/DB:1792158069233 2026-10-16T13:41:09.233Z daily 0.9 https://cdn.brandfetch.io/DB/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Deutsche Bank prepares crypto custody launch, targets Asia growth' - Reuters Deutsche Bank is set to launch a crypto custody service as part of its strategy to expand in the Asian market. The initiative aims to cater to the growing demand for digital asset management in the region. This move aligns with the bank's broader efforts to enhance its offerings in the financial technology sector. https://www.openbell.ai/news/PRAX:1792157872971 2026-10-16T13:37:52.971Z daily 0.9 https://cdn.brandfetch.io/PRAX/w/400/h/400?c=1idopYfmtR7ZKg8QMud JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700 JP Morgan analyst Tessa Romero has initiated coverage on Praxis Precision Medicine (NASDAQ: PRAX) with an Overweight rating. The firm has set a price target of $700 for the stock. https://www.openbell.ai/news/MSFT:1792157820059 2026-10-16T13:37:00.059Z daily 0.9 https://cdn.brandfetch.io/MSFT/w/400/h/400?c=1idopYfmtR7ZKg8QMud StoneX Maintains Buy on Microsoft, Raises Price Target to $600 StoneX analyst Yi Fu Lee has maintained a Buy rating on Microsoft (NASDAQ: MSFT) and increased the price target from $525 to $600. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/ECHO:1792157736952 2026-10-16T13:35:36.952Z daily 0.9 https://cdn.brandfetch.io/ECHO/w/400/h/400?c=1idopYfmtR7ZKg8QMud JP Morgan Upgrades EchoStar to Overweight, Announces $144 Price Target JP Morgan analyst Sebastiano Petti has upgraded EchoStar (NASDAQ: ECHO) from Underweight to Overweight, setting a price target of $144 for the stock. This upgrade reflects a positive outlook on the company's performance. https://www.openbell.ai/news/LOOP:1792157732605 2026-10-16T13:35:32.605Z daily 0.9 https://cdn.brandfetch.io/LOOP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Loop Industries shares are trading lower after the company reported worse-than-expected Q2 sales results. openbell Financial News https://www.openbell.ai/news/TOL:1792157682898 2026-10-16T13:34:42.898Z daily 0.9 https://cdn.brandfetch.io/TOL/w/400/h/400?c=1idopYfmtR7ZKg8QMud StoneX Initiates Coverage On Toll Brothers with Buy Rating, Announces Price Target of $165 StoneX analyst Michael Rindos has initiated coverage on Toll Brothers (NYSE: TOL) with a Buy rating. The analyst has set a price target of $165 for the company's stock. https://www.openbell.ai/news/FMC:1792157374092 2026-10-16T13:29:34.092Z daily 0.9 https://cdn.brandfetch.io/FMC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jefferies Downgrades FMC to Hold, Lowers Price Target to $5 Jefferies analyst Laurence Alexander has downgraded FMC (NYSE: FMC) from a Buy rating to a Hold rating. Additionally, the price target for FMC has been reduced significantly from $14 to $5. https://www.openbell.ai/news/WAY:1792157344290 2026-10-16T13:29:04.290Z daily 0.9 https://cdn.brandfetch.io/WAY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on Waystar Holding, Raises Price Target to $35 Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Waystar Holding (NASDAQ: WAY) and increased the price target from $30 to $35. This adjustment reflects a positive outlook for the company's performance in the market. https://www.openbell.ai/news/VRNS:1792157334731 2026-10-16T13:28:54.731Z daily 0.9 https://cdn.brandfetch.io/VRNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Varonis to Go Private in $6.3 Billion Takeover Varonis Systems Inc. is set to be acquired by Proofpoint Inc. in an all-cash deal valued at approximately $6.3 billion, offering Varonis shareholders $49.75 per share. This represents a 52% premium over Varonis' closing price on June 22 and a 17% premium over its price on September 1. The deal has been unanimously approved by Varonis' board and is expected to close in the first half of 2027, pending shareholder and regulatory approvals. Following the acquisition, Varonis will become a privately held company. https://www.openbell.ai/news/VRNS:1792157325627 2026-10-16T13:28:45.627Z daily 0.9 https://cdn.brandfetch.io/VRNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Varonis to Go Private in $6.3 Billion Takeover Varonis Systems Inc. (NASDAQ: VRNS) will be acquired by Proofpoint Inc. in an all-cash deal valued at approximately $6.3 billion, or $49.75 per share, representing a 52% premium over its June 22 closing price. The transaction has been unanimously approved by Varonis' board and is expected to close in the first half of 2027, pending shareholder and regulatory approvals. Following the acquisition, Varonis will become privately held, ceasing to trade on Nasdaq. The deal is financed by Thoma Bravo and includes commitments from Ontario Teachers’ Pension Plan. https://www.openbell.ai/news/VRNS:1792157259500 2026-10-16T13:27:39.500Z daily 0.9 https://cdn.brandfetch.io/VRNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Varonis to Go Private in $6.3 Billion Takeover Varonis Systems Inc. (NASDAQ: VRNS) will be acquired by Proofpoint Inc. in an all-cash deal valued at approximately $6.3 billion, or $49.75 per share, representing a 52% premium to its June 22 closing price. The acquisition, which has been unanimously approved by Varonis' board, is expected to close in the first half of 2027, pending shareholder and regulatory approvals. Following the deal, Varonis will become a privately held company, ceasing to trade on Nasdaq. Varonis is scheduled to report its third-quarter earnings on November 3, 2026, but will not hold an earnings call due to the transaction. https://www.openbell.ai/news/VRNS:1792157247418 2026-10-16T13:27:27.418Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/MA.jpg?width=250&height=187 Varonis to Go Private in $6.3 Billion Takeover Varonis Systems Inc. (NASDAQ: VRNS) is set to be acquired by Proofpoint Inc. in an all-cash deal valued at approximately $6.3 billion, or $49.75 per share, representing a 52% premium over its June 22 closing price. The acquisition, which has been unanimously approved by Varonis' board, is expected to close in the first half of 2027, pending shareholder and regulatory approvals. Following the transaction, Varonis will become a privately held company, ceasing to trade on Nasdaq, while Thoma Bravo is providing the necessary financing for the deal. https://www.openbell.ai/news/SDGR:1792157222027 2026-10-16T13:27:02.027Z daily 0.9 https://cdn.brandfetch.io/SDGR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on Schrodinger, Raises Price Target to $32 Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Schrodinger (NASDAQ: SDGR) and raised the price target from $20 to $32. This adjustment reflects a positive outlook for the company's performance. https://www.openbell.ai/news/HNGE:1792157123967 2026-10-16T13:25:23.967Z daily 0.9 https://cdn.brandfetch.io/HNGE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on Hinge Health, Raises Price Target to $140 Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Hinge Health (NYSE: HNGE) and raised the price target from $125 to $140. This adjustment reflects a positive outlook for the company's performance in the market. https://www.openbell.ai/news/VRNS:1792157123140 2026-10-16T13:25:23.140Z daily 0.9 https://cdn.brandfetch.io/VRNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Varonis to Go Private in $6.3 Billion Takeover Varonis Systems Inc. (NASDAQ: VRNS) is set to be acquired by Proofpoint Inc. in an all-cash deal valued at approximately $6.3 billion, equating to $49.75 per share. This offer represents a 52% premium over Varonis' closing price of $32.71 on June 22 and a 17% premium over its price of $42.35 on September 1. The transaction has been unanimously approved by Varonis' board and is expected to close in the first half of 2027, pending shareholder and regulatory approvals. Following the acquisition, Varonis will become a privately held company, and its shares will cease trading on Nasdaq. https://www.openbell.ai/news/CON:1792157063711 2026-10-16T13:24:23.711Z daily 0.9 https://cdn.brandfetch.io/CON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jefferies Initiates Coverage On Concentra Group Holdings with Buy Rating, Announces Price Target of $47 Jefferies analyst Jack Slevin has initiated coverage on Concentra Group Holdings (NYSE: CON) with a Buy rating. The firm has set a price target of $47 for the company's stock. https://www.openbell.ai/news/VRNS:1792156943032 2026-10-16T13:22:23.032Z daily 0.9 https://cdn.brandfetch.io/VRNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jefferies Downgrades Varonis Systems to Hold, Lowers Price Target to $49.75 Jefferies analyst Joseph Gallo has downgraded Varonis Systems (NASDAQ: VRNS) from a Buy rating to Hold. Additionally, the price target for the stock has been reduced from $60 to $49.75. https://www.openbell.ai/news/MBRX:1792156907452 2026-10-16T13:21:47.452Z daily 0.9 https://cdn.brandfetch.io/MBRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20 Moleculin Biotech has announced a 1-for-20 reverse stock split effective October 20, 2026, which will reduce the number of outstanding shares from approximately 20.9 million to about 1.05 million. The reverse stock split will not change the nominal par value of $0.001 per share, and no fractional shares will be issued; instead, stockholders will receive cash for any fractional shares. The company's common stock will continue to trade under the ticker symbol 'MBRX' on The Nasdaq Capital Market following the split. https://www.openbell.ai/news/VCYT:1792156754421 2026-10-16T13:19:14.421Z daily 0.9 https://cdn.brandfetch.io/VCYT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program Veracyte, Inc. (Nasdaq: VCYT) announced that its Prosigna Breast Risk of Recurrence test has received coverage through Palmetto GBA’s MolDX program, establishing a reimbursement path for eligible early-stage breast cancer patients. This coverage, effective August 19, 2026, applies to postmenopausal women with early-stage estrogen receptor positive breast cancer meeting specific Medicare criteria. The decision supports broader adoption of the test following its U.S. launch in June 2026. https://www.openbell.ai/news/CRWD:1792156748554 2026-10-16T13:19:08.554Z daily 0.9 https://cdn.brandfetch.io/CRWD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $265 Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on CrowdStrike Holdings (NASDAQ: CRWD) and increased the price target from $245 to $265. This adjustment reflects a positive outlook for the company's performance in the market. https://www.openbell.ai/news/CERT:1792156658322 2026-10-16T13:17:38.322Z daily 0.9 https://cdn.brandfetch.io/CERT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on Certara, Raises Price Target to $12 Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Certara (NASDAQ: CERT) and raised the price target from $9 to $12. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/SPY:1792156610827 2026-10-16T13:16:50.827Z daily 0.9 https://cdn.brandfetch.io/SPY/w/400/h/400?c=1idopYfmtR7ZKg8QMud USA Industrial Production (YoY) For September 2.2% Vs 1.4% Prior openbell Financial News https://www.openbell.ai/news/ABSI:1792156578544 2026-10-16T13:16:18.544Z daily 0.9 https://cdn.brandfetch.io/ABSI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Maintains Overweight on Absci, Raises Price Target to $20 Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Absci (NASDAQ: ABSI) and raised the price target from $16 to $20. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/SKHY:1792156488443 2026-10-16T13:14:48.443Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/AI-investing.jpg?width=250&height=187 EXCLUSIVE: Is AI Growth Slowing Down? Memory Industry Expert Says It's 'Too Early' To Tell Memory chip stocks experienced significant declines, with SK Hynix Inc. falling 24.3% and Samsung Electronics losing 17.7% over the past week. Micron Technology's stock closed at $931.24, down 9.5% and approximately 26% below its record high. Despite these losses, MS Hwang from Counterpoint Research suggests it is premature to conclude that AI growth is slowing, attributing the sell-off to financial factors such as inflation and interest rates rather than supply issues from Chinese competitors. https://www.openbell.ai/news/AAPL:1792156475108 2026-10-16T13:14:35.108Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Mexico-City--Mexico--09-09-2026--Screen-.jpg?width=250&height=187 Apple Stock Hits Record High as iPhone Duo Pre-Orders Sell Out in Minutes Apple Inc. (NASDAQ: AAPL) shares rose over 2% in premarket trading, reaching a record high of $348.14, following reports that pre-orders for the iPhone Duo sold out within minutes. Shipping dates for the device quickly slipped to November 16 and 23, indicating strong demand, although analysts suggest that limited supply due to manufacturing delays may skew the sellout's significance. In contrast, pre-orders for the iPhone 18 Pro were reportedly slow, leading Apple to cut component orders by 15% to 20% for that model. https://www.openbell.ai/news/FOX:1792156077654 2026-10-16T13:07:57.654Z daily 0.9 https://cdn.brandfetch.io/FOX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Fox shares are trading higher after B of A Securities upgraded the stock from Underperform to Buy rating and raised its price target from $54 to $85. openbell Financial News https://www.openbell.ai/news/TLT:1792155873706 2026-10-16T13:04:33.706Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Us-Savings-Bonds--Savings-Bonds-Are-Debt.jpg?width=250&height=187 AI Bubble Worries Hand Long-Term Treasuries Their Best Week Since March 2025 The iShares 20+ Year Treasury Bond ETF (NASDAQ: TLT) rose 2.55% this week to $79.97, marking its best week since March 2025, despite inflation reports showing consumer prices rose 0.6% in September, pushing annual inflation to 3.7%. The 10-year Treasury yield fell to 5.10%, down 14 basis points, as investors shifted focus to long-dated Treasuries amid concerns over a slowdown in AI spending, with Gartner estimating a $3.5 trillion exposure to write-downs in AI infrastructure. The Invesco QQQ Trust (NASDAQ: QQQ) also declined 3.1% this week, reflecting broader market impacts from these developments. https://www.openbell.ai/news/NAVN:1792155810840 2026-10-16T13:03:30.840Z daily 0.9 https://cdn.brandfetch.io/NAVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Navan Says Several Of Its AI Travel Agents In Production Are Being Powered By Nvidia Nemotron 3.5 Super VL Navan has successfully deployed several AI travel agents powered by NVIDIA's Nemotron 3.5 Super VL model, following a three-week evaluation and training period. This deployment reflects Navan's strategy of utilizing both open and closed models to enhance its AI capabilities in the travel sector. The Nemotron model outperformed competitors in six out of seven performance measures, including latency, and is expected to reduce costs while increasing value for users. https://www.openbell.ai/news/SGRX:1792155716094 2026-10-16T13:01:56.094Z daily 0.9 https://cdn.brandfetch.io/SGRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud SANGRIX Announces 16 B300 Servers Schedules To Be Delivered During Week Of Nov. 3 SANGRIX INC. (Nasdaq: SGRX), formerly known as Bit Origin Ltd, announced that 16 NVIDIA Blackwell B300 servers are scheduled for delivery during the week of November 3, 2026. This delivery marks a significant step in establishing the company's AI computing capacity in Malaysia, with the servers comprising 128 NVIDIA B300 GPUs. The infrastructure is being supplied by PT MITRA MANUNGGAL SANGKARA. https://www.openbell.ai/news/VRNS:1792155516400 2026-10-16T12:58:36.400Z daily 0.9 https://cdn.brandfetch.io/VRNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Varonis System shares are trading higher after the company announced that it will be taken private by Thoma Bravo at $49.75 per share in cash. openbell Financial News https://www.openbell.ai/news/JNJ:1792155477799 2026-10-16T12:57:57.799Z daily 0.9 https://cdn.brandfetch.io/JNJ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma The Committee for Medicinal Products for Human Use has recommended the approval of an indication extension for Johnson & Johnson's TALVEY (talquetamab) to treat adults with relapsed or refractory multiple myeloma. This recommendation could potentially expand the drug's use in earlier line treatments. The approval process is a significant step for JNJ as it seeks to enhance its portfolio in oncology. https://www.openbell.ai/news/TCEHY:1792155351906 2026-10-16T12:55:51.906Z daily 0.9 https://cdn.brandfetch.io/TCEHY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reported October 15, 'DeepSeek offers user refunds after suffering another major outage' - SCMP DeepSeek has announced it will offer refunds to users following a significant outage that affected its services. This incident marks another major disruption for the company, which has faced similar issues in the past. The stock ticker for DeepSeek is TCEHY. https://www.openbell.ai/news/POM:1792155321582 2026-10-16T12:55:21.582Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/16-10-2026-134311-thebambooworks-com.jpg?width=250&height=187 Pomdoctor In Nasdaq’s Delisting List Pomdoctor Ltd. (NASDAQ: POM) is facing potential delisting from the Nasdaq due to its stock trading below $1 for 30 consecutive days, a situation exacerbated by a recent 18-for-1 reverse share split. The company's stock has plummeted from an IPO price of $4 to approximately $0.71, resulting in a market capitalization of $6.6 million. Despite a revenue increase to 185 million yuan ($27.6 million) in the first half of this year, losses surged to 238 million yuan, primarily due to rising operating expenses. The Nasdaq's expedited delisting policy, aimed at addressing suspicious Chinese listings, could lead to Pomdoctor's shares being suspended as early as October 15 unless an appeal is filed. https://www.openbell.ai/news/HSTM:1792154949941 2026-10-16T12:49:09.941Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Healthcare-stocks.jpg?width=250&height=187 Top 3 Health Care Stocks That May Fall Off A Cliff In October As of October 16, 2026, three health care stocks are identified as potentially overbought, with significant momentum indicators. Option Care Health (NASDAQ: OPCH) was downgraded by UBS from Buy to Neutral, with a price target cut from $39 to $32.05, despite a recent 28% stock gain. Pacira Biosciences (NASDAQ: PCRX) announced its acquisition by Viatris, with a stock increase of 46% over the past month, while HealthStream (NASDAQ: HSTM) received a Hold rating from Freedom Capital Markets with a price target of $36, following a 15% stock rise. https://www.openbell.ai/news/WDAY:1792154940486 2026-10-16T12:49:00.486Z daily 0.9 https://cdn.brandfetch.io/WDAY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Downgrades Workday to Sector Perform Keybanc analyst Jason Celino has downgraded Workday (NASDAQ: WDAY) from an Overweight rating to Sector Perform. This change reflects a shift in the analyst's outlook on the company's performance relative to its sector. https://www.openbell.ai/news/SCHW:1792154798310 2026-10-16T12:46:38.310Z daily 0.9 https://cdn.brandfetch.io/SCHW/w/400/h/400?c=1idopYfmtR7ZKg8QMud Citizens Reiterates Market Outperform on Charles Schwab, Maintains $120 Price Target Citizens analyst Devin Ryan has reiterated a Market Outperform rating on Charles Schwab (NYSE: SCHW) while maintaining a price target of $120. This reflects confidence in the company's performance in the market. https://www.openbell.ai/news/PPCB:1792154788977 2026-10-16T12:46:28.977Z daily 0.9 https://cdn.brandfetch.io/PPCB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer Propanc Biopharma, Inc. (Nasdaq: PPCB) has announced new preclinical research indicating that its pancreatic proenzyme formulation, PRP, may serve as a potential strategy to combat chemotherapy resistance in pancreatic cancer. This research was conducted in collaboration with the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo. https://www.openbell.ai/news/PPCB:1792154723259 2026-10-16T12:45:23.259Z daily 0.9 https://cdn.brandfetch.io/PPCB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer Propanc Biopharma, Inc. (Nasdaq: PPCB) has announced new preclinical research indicating that its pancreatic proenzyme formulation, PRP, may serve as a potential strategy to combat chemotherapy resistance in pancreatic cancer. This research is a result of a collaboration between the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo. https://www.openbell.ai/news/ETHUSD:1792154688853 2026-10-16T12:44:48.853Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Cryptocurrency-Coins-Displaying-XRP--Sol.jpg?width=250&height=187 Bitcoin, Ethereum or Solana? Raoul Pal Calls One 'Wildly Undervalued' Raoul Pal, CEO of Real Vision, has labeled Ethereum (CRYPTO: ETH) as 'wildly undervalued,' arguing that the market has not accounted for the potential loss of $1 trillion to $1.5 trillion in value if the network were to shut down. He emphasizes that Ethereum's significance extends beyond cash flow, as it supports a vast portion of stablecoins and DeFi activity. Pal maintains a buy-the-dip strategy and believes that a liquidity shift back towards crypto is imminent, driven by expected rate cuts and increased capital expenditure. https://www.openbell.ai/news/JBHT:1792154417524 2026-10-16T12:40:17.524Z daily 0.9 https://cdn.brandfetch.io/JBHT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Citizens Reiterates Market Outperform on JB Hunt Transport Servs, Maintains $300 Price Target Citizens analyst Jeff Kauffman has reiterated a Market Outperform rating on JB Hunt Transport Services (NASDAQ: JBHT) and has maintained a price target of $300 for the stock. https://www.openbell.ai/news/AAPL:1792154328478 2026-10-16T12:38:48.478Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Bangkok-Thailand-Sep-19-2026-Apple-Iphon.jpg?width=250&height=187 Apple’s $1,999 iPhone Duo Preorders Begin Today: Trade-Ins, Monthly Payments and Deals to Cut the Hefty Price Apple Inc. (NASDAQ: AAPL) has begun accepting preorders for its new iPhone Duo, priced at $1,999, starting October 16. Customers can benefit from trade-in credits ranging from $175 to $885 for eligible devices and financing options, including a 24-month lease starting at $57.99 per month. Apple is reportedly increasing supply-chain orders for the iPhone Duo by 30%, raising initial production estimates from 6-7 million units to nearly 10 million due to underestimated demand. As of October 13, Apple shares reached an all-time high, trading 1.83% higher at $348.26 during pre-market trading. https://www.openbell.ai/news/ATNM:1792154272955 2026-10-16T12:37:52.955Z daily 0.9 https://cdn.brandfetch.io/ATNM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Actinium Pharma To Present Preclinical Data Supporting ATNM-400's Broad Potential At 39th Annual Congress Of EANM Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is set to present preclinical data on its radiotherapy ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine from October 17-21, 2026. The data highlight ATNM-400's antitumor activity in non-small cell lung cancer (NSCLC), colorectal cancer, and ovarian cancer, demonstrating its potential as both a monotherapy and in combination with standard treatments. The findings support mutation-agnostic development and suggest that ATNM-400 could enhance responses to existing therapies, particularly in treatment-resistant cancer models. https://www.openbell.ai/news/IRD:1792154249464 2026-10-16T12:37:29.464Z daily 0.9 https://cdn.brandfetch.io/IRD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target Citizens analyst Jonathan Wolleben has reiterated a Market Outperform rating for Opus Genetics (NASDAQ: IRD) and has maintained a price target of $17 for the stock. https://www.openbell.ai/news/TRAX:1792154207010 2026-10-16T12:36:47.010Z daily 0.9 https://cdn.brandfetch.io/TRAX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90 Leerink Partners analyst David Risinger has maintained an 'Outperform' rating on First Tracks (NASDAQ: TRAX) and raised the price target from $70 to $90. This adjustment reflects a positive outlook for the company's performance in the market. https://www.openbell.ai/news/FWONK:1792154096335 2026-10-16T12:34:56.335Z daily 0.9 https://cdn.brandfetch.io/FWONK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Susquehanna Maintains Positive on Liberty Media, Lowers Price Target to $110 Susquehanna analyst Joseph Stauff has maintained a Positive rating on Liberty Media (NASDAQ: FWONK) but has lowered the price target from $114 to $110. This adjustment reflects a change in the analyst's outlook while still indicating a favorable view of the company's performance. https://www.openbell.ai/news/LADR:1792154011194 2026-10-16T12:33:31.194Z daily 0.9 https://cdn.brandfetch.io/LADR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ladder Cap Q3 Adj. EPS $0.35 Beats $0.31 Estimate, Sales $118.904M Beat $79.433M Estimate Ladder Cap (NYSE:LADR) reported Q3 adjusted earnings per share of $0.35, exceeding the analyst estimate of $0.31 by 12.9%, and reflecting a 40% increase from $0.25 per share in the same quarter last year. The company's sales reached $118.904 million, surpassing the expected $79.433 million by 49.69%, and marking a 106.99% increase from $57.444 million in the prior year. https://www.openbell.ai/news/SPY:1792154003841 2026-10-16T12:33:23.841Z daily 0.9 https://cdn.brandfetch.io/SPY/w/400/h/400?c=1idopYfmtR7ZKg8QMud USA Export Price Index (MoM) For September 2.2% Vs 1.0% Est. openbell Financial News https://www.openbell.ai/news/UBER:1792153971672 2026-10-16T12:32:51.672Z daily 0.9 https://cdn.brandfetch.io/UBER/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Reiterates Buy on Uber Technologies, Maintains $125 Price Target Guggenheim analyst Taylor Manley has reiterated a Buy rating on Uber Technologies (NYSE: UBER) and maintained a price target of $125. This endorsement reflects confidence in the company's performance and potential growth. https://www.openbell.ai/news/QMLS:1792153890301 2026-10-16T12:31:30.301Z daily 0.9 https://cdn.brandfetch.io/QMLS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Compass Point Initiates Coverage On QumulusAI with Buy Rating, Announces Price Target of $9 Compass Point analyst Michael Donovan has initiated coverage on QumulusAI (NASDAQ: QMLS) with a Buy rating. The analyst has set a price target of $9 for the company's stock.